Find Clinical Trials

October 20, 2022 in Gastrointestinal (GI)

Actuate 1801

Study Protocol 1801, Part 3 Arm B: Randomized Phase 2 Study of Gemcitabine/Nab-Paclitaxel Plus 9-ING-41 in Patients with Previously Untreated Metastatic Pancreatic Cancer
Read More
October 14, 2022 in Gastrointestinal (GI)

SGNTUC-029

An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with…
Read More
October 11, 2022 in Gastrointestinal (GI)

S2107

Randomized Phase II trial of encorafenib and cetuximab with or without nivolumab (NSC #748726) for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer (NCT #05308446)
Read More
September 14, 2022 in Gastrointestinal (GI)

GI003

GI003: A Phase III Randomized Trial of Protons Versus Photons For Hepatocellular Carcinoma
Read More
August 31, 2022 in Gastrointestinal (GI)

C-14 (CORRECT-MRD II)

CORRECT-MRD II: Second COloRectal cancer clinical validation study to predict REcurrence using a Circulating Tumor DNA assay to detect Minimal Residual Disease
Read More
July 11, 2022 in Gastrointestinal (GI)

WF1806

WF-1806: Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M and M Study (NCT03998202)
Read More
July 11, 2022 in Gastrointestinal (GI)

S2001

S2001: Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations
Read More
July 11, 2022 in Gastrointestinal (GI)

S1922

S1922: Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Read More
July 1, 2022 in Gastrointestinal (GI)

KRYSTAL-10

KRYSTAL-10: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After…
Read More
June 30, 2022 in Gastrointestinal (GI)

GI008

GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) (NCT 05174169)
Read More
June 30, 2022 in Gastrointestinal (GI)

GI006

GI006: Phase III Randomized Trial of Proton Beam Therapy (PBT) versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Read More
June 30, 2022 in Gastrointestinal (GI)

GI005

GI005: Phase II/III study of Circulating tumor DNA as a predictive BiomaRker in Adjuvant chemotherapy in stage IIA colon cancer (COBRA)
Read More
June 30, 2022 in Gastrointestinal (GI)

GI004

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Atezolizumab Combination versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch…
Read More
June 30, 2022 in Gastrointestinal (GI)

EA2201

EA2201: A Phase II Study of Neoadjuvant Nivolumab plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
Read More
June 30, 2022 in Gastrointestinal (GI)

EA2187

EA2187: A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
Read More
June 30, 2022 in Gastrointestinal (GI)

EA2186

EA2186, A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT) (NCT)
Read More
June 30, 2022 in Gastrointestinal (GI)

EA2183

EA2183: A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic Esophageal and Gastric Adenocarcinoma
Read More
June 30, 2022 in Gastrointestinal (GI)

EA2182

EA2182: A Randomized Phase II Study of De-intensified Chemoradiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)
Read More
June 30, 2022 in Gastrointestinal (GI)

EA2176

EA2176: A Phase III Study of Immune checkpoint inhibition with chemotherapy in treatment-naïve metastatic anal cancer patients
Read More
June 29, 2022 in Gastrointestinal (GI)

A021602

Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Everolimus
Read More